GSK: Double Bottom detected on 20 Oct 2026

GSK is forming a double_bottom pattern with confluence from a three_white_soldiers rally (formed Oct 15, 62.97% win probability). The structure score of 13.12/15 and volume score of 9.82/12 indicate solid technical foundation. Price sits at $49.46, between key support at $45.82 and resistance at $55.28. The breakout score of 11.92/13 suggests moderate momentum confirmation. RSI at 56.01 shows neutral positioning (not overbought). Current volume at 5.37M shares is near the 20-day average, providing modest confirmation. The overall score of 60.86/98 reflects a moderately attractive setup with 19.58% upside from the 52-week low.

GSK reported Q2 2026 earnings that beat expectations substantially, with core EPS up 9% year-over-year and specialty medicines (particularly oncology and HIV) rising 14%. GSK's latest catalyst is strong early lung-cancer data for its experimental ADC risvutatug rezetecan, which showed a 61% confirmed response rate at the higher dose in an early global trial. Analysts reaffirmed a bullish view, with Q3 revenue and EPS expected broadly in line, HIV strength partly offsetting vaccine headwinds. Earnings are scheduled for Oct 28, 2026—one week after pattern detection. HIV business continues to outperform with sales growing 10% in Q2, driven by long-acting injectables like Cabenuva. However, General Medicines sales declined 9% in Q2 due to pricing pressure on Trelegy and a softer inhaled respiratory market. The sector regime is bullish (0.94 score), supporting strength in healthcare equities.

A confirmed breakout above resistance at $55.28 would validate the double_bottom reversal. The measured move target of $51.80 (conservative estimate) implies ~4.7% upside from current price. Volume confirmation is key—breakout volume should exceed the current 5.37M share average. Historical data supports 62.97% probability of success. Invalidation occurs at key support of $45.82, representing ~7.4% downside risk. Beta of 0.63 indicates lower volatility than the broad market, suggesting this pattern may develop more gradually. The three_white_soldiers auxiliary pattern adds technical corroboration to the reversal thesis.

Earnings release Oct 28 creates binary event risk within the pattern window—stock has historically moved 3-5% on earnings surprises. GSK reported a significant impairment charge for Camlipixant following failure of the CALM-2 study in chronic cough, highlighting pipeline risks. Dolutegravir, a key HIV drug, faces loss of exclusivity in 2028-2030, which will pressure revenue and margins. EPS guidance was lowered to the lower half of the range, primarily due to additional interest costs from the Nuvalent acquisition. Volume ratio at 0.95 shows slightly below-average trading activity, potentially limiting follow-through on breakout. Stock is down 1.51% over one month despite recent rally, suggesting lingering distribution. ATR of 0.98 (1.98% of price) indicates manageable daily swings for risk management.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.